See Accompanying Notes to
Condensed Consolidated Financial Statements.
See Accompanying Notes
to Condensed Consolidated Financial Statements.
Notes
to the Condensed Consolidated Financial Statements
Three
Months Ended March 31, 2022 and 2021
Note
1 Organization & Nature of Operations
Progressive
Care Inc. (“Progressive”) was incorporated under the laws of the state of Delaware on October 31, 2006.
Progressive,
through its wholly-owned subsidiaries, PharmCo, LLC (referred to as “PharmCo 901”), Touchpoint RX, LLC doing business as
PharmCo Rx 1002, LLC (referred to as “PharmCo 1002”), Family Physicians RX, Inc. doing business as PharmCoRx 1103 and PharmCoRx
1204 (referred to as “FPRX” historically or “PharmCo 1103” and “PharmCo 1204” currently) (pharmacy
subsidiaries collectively referred to as “PharmCo”), and ClearMetrX Inc. (collectively with all entities referred to as the
“Company”, or “we”) is a personalized healthcare services and technology company that provides prescription pharmaceuticals
and risk and data management services to healthcare organizations and providers.
PharmCo
901 was formed on November 29, 2005 as a Florida Limited Liability Company and is a 100% owned subsidiary of Progressive. PharmCo 901
was acquired by Progressive on October 21, 2010. We currently deliver prescriptions to Florida’s diverse population and ship medications
to patients in states where we hold non-resident pharmacy licenses as well. We currently hold Florida Community Pharmacy Permits at all
Florida pharmacy locations and our PharmCo 901 location is licensed as a non-resident pharmacy in the following states: Arizona, Colorado,
Connecticut, Georgia, Illinois, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Texas, and Utah. We are able to dispense to patients
in the state of Massachusetts without a non-resident pharmacy license because Massachusetts does not require such a license for these
activities.
PharmCo
1103 is a pharmacy with locations in North Miami Beach and Orlando, Florida that provides PharmCo’s pharmacy services to Broward
County, the Orlando/Tampa corridor, and the Treasure Coast of Florida. Progressive acquired all of the ownership interests in PharmCo
1103 in a purchase agreement entered into on June 1, 2019.
PharmCo
1002 is a pharmacy located in Palm Springs, Florida that provides PharmCo’s pharmacy services to Palm Beach, St. Lucie and Martin
Counties, Florida. Progressive acquired all of the ownership interests in PharmCo 1002 in a purchase agreement entered into on July 1,
2018.
ClearMetrX
was formed on June 10, 2020 and provides third party administration services to 340B covered entities. ClearMetrX also provides data
analytics and reporting services to support and improve care management for health care organizations.
Note
2 Basis of Presentation
The
Company’s fiscal year end is December 31. The Company uses the accrual method of accounting. The accompanying unaudited interim
condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. The
December 31, 2021 balance sheet has been derived from audited consolidated financial statements.
The accompanying unaudited condensed consolidated financial
statements for the three months ended March 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted
in the United States of America for interim financial information and pursuant to the rules and regulations of the Securities and Exchange
Commission. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in
the United States of America for complete financial statements.
The unaudited financial information included in this
report includes all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary to reflect
a fair statement of the results for the interim periods. The results of operations for the three months ended March 31, 2022 are not
necessarily indicative of the results of the full fiscal year.
The condensed consolidated financial statements included
in this report should be read in conjunction with the financial statements and notes thereto included in the Company’s financial
statements for the fiscal year ended December 31, 2021.
Note
3 Summary of Significant Accounting Policies
Principles
of Consolidation
The
condensed consolidated financial statements include the accounts of Progressive and its wholly-owned subsidiaries. All inter-company
accounts and transactions have been eliminated in consolidation.
Use
of Estimates
The
preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the
United States of America (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported
in the condensed consolidated financial statements and accompanying notes. Such estimates and assumptions impact both assets and
liabilities, including but not limited to: net realizable value of accounts receivable and inventories, estimated useful lives and potential
impairment of property and equipment, estimated fair value of derivative liabilities using the Monte Carlo simulation model, fair value
of assets acquired and liabilities assumed in business combinations, and estimates of current and deferred tax assets and liabilities.
Making
estimates requires management to exercise significant judgment. The full extent to which the COVID-19 pandemic will directly or indirectly
impact our business, results of operations and financial condition, including sales, expenses, and reserves and allowances, will depend
on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the
actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, and national customers and markets.
We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes
to those estimates in future periods. Actual results may differ from these estimates.
Reclassifications
Certain reclassifications have been made to the
2021 financial statement presentation to conform to that of the current period. Total equity and net income are unchanged due
to these reclassifications.
Cash
and Cash Equivalents
The
Company maintains its cash and cash equivalents in bank deposit accounts which, at times, may exceed federally insured limits. The Company
had $1,250,375 in excess cash at March 31, 2022. The Company has not experienced any losses in such accounts. The Company believes it
is not exposed to any significant credit risk associated with its cash and cash equivalent balances, since our deposits are held with
high quality financial institutions that are well capitalized,
Cash
Equivalents: The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash
equivalents. As of March 31, 2022 and December 31, 2021, the Company’s cash equivalents consist of a money market account.
Accounts
Receivable and Allowance for Doubtful Accounts
Trade
accounts receivable are stated at the invoiced amount. Trade accounts receivable primarily include amounts from third-party pharmacy
benefit managers and insurance providers and are based on contracted prices. Trade accounts receivable are unsecured and require no collateral.
The Company records an allowance for doubtful accounts for estimated differences between the expected and actual payment of accounts
receivable. These reductions were made based upon reasonable and reliable estimates that were determined by reference to historical experience,
contractual terms, and current conditions. Each quarter, the Company reevaluates its estimates to assess the adequacy of its allowance
and adjusts the amounts as necessary. Account balances are charged off against the allowance after all means of collection have been
exhausted and the potential for recovery is considered remote.
Risks
and Uncertainties
The
Company’s operations are subject to intense competition, risk and uncertainties including financial, operational, regulatory and
other risks including the potential risk of business failure.
Billing
Concentrations
The
Company’s trade receivables are primarily from prescription medications billed to various insurance providers. Ultimately, the
insured is responsible for payment should the insurance company not reimburse the Company. The Company generated reimbursements from
three significant insurance providers for the period ended March 31, 2022:
Schedule
of Billing Concentrations
Reimbursement
percentage
The
Company generated reimbursements from three significant pharmacy benefit managers (PBMs) for the period ended March 31, 2022:
Inventory
Inventory
is valued on a lower of first-in, first-out (FIFO) cost or net realizable value basis. Inventory primarily consists of prescription medications,
pharmacy and testing supplies, and retail items. The Company provides a valuation allowance for obsolescence and slow-moving items. The
Company recorded an allowance for obsolescence of $40,000 as of March 31, 2022 and December 31, 2021, respectively.
Property
and Equipment
Property
and equipment are recorded at cost or fair value if acquired as part of a business combination. Property and equipment are depreciated
or amortized using the straight-line method over their estimated useful lives. Upon the retirement or disposition of property and equipment,
the related cost and accumulated depreciation or amortization are removed, and a gain or loss is recorded, when appropriate. Expenditures
for maintenance and repairs are charged to expense as incurred. Estimated useful lives of property and equipment are as follows:
Schedule
of Estimated Useful Lives of Property and Equipment
Description |
|
Estimated
Useful Life |
Building |
|
40
years |
Leasehold
improvements and fixtures |
|
Lesser
of estimated useful life or life of lease |
Furniture
and equipment |
|
5
years |
Computer
equipment and software |
|
3
years |
Vehicles |
|
3-5
years |
Property
and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may
not be recoverable. There were no impairment charges during the periods ended March 31, 2022 and 2021, respectively.
Business
acquisitions
The
Company records business acquisitions using the acquisition method of accounting. All of the assets acquired, liabilities assumed, and
contractual contingencies are recognized at their fair value on the acquisition date. The application of the acquisition method of accounting
for business combinations requires management to make significant estimates and assumptions in the determination of the fair value of
assets acquired and liabilities assumed in order to properly allocate purchase price consideration between assets that are depreciated
and amortized and goodwill. The excess of the fair value of purchase consideration over the fair values of these identifiable assets
and liabilities is recorded as goodwill. Acquisition-related expenses and restructuring costs are recognized separately from the business
combination and are expensed as incurred.
Goodwill
Goodwill
represents the excess of the purchase price of FPRX and PharmCo 1002 over the value assigned to their net tangible and identifiable intangible
assets. FPRX and PharmCo 1002 are considered to be the reporting units for goodwill. Acquired intangible assets other than goodwill are
amortized over their useful lives unless the lives are determined to be indefinite. For intangible assets purchased in a business combination,
the estimated fair values of the assets received are used to establish their recorded values. Valuation techniques consistent with the
market approach, income approach, and/or cost approach are used to measure fair value. Goodwill and other indefinite-lived intangible
assets are tested annually for impairment in the fourth fiscal quarter and in interim periods if events or changes in circumstances indicate
that the assets may be impaired.
Intangible
Assets
Amortizing
identifiable intangible assets generally represent the cost of client relationships and tradenames acquired, as well as non-compete agreements
to which the Company is a party. In valuing these assets, the Company makes assumptions regarding useful lives and projected growth rates,
and significant judgment is required. The Company periodically reviews its identifiable intangible assets for impairment as events or
changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If the carrying amounts of those assets
exceed their respective fair values, additional impairment tests are performed to measure the amount of the impairment losses, if any.
Fair
Value Measurements
Financial
Accounting Standards Board Accounting Standards Codification (“FASB ASC”) Topic 820 establishes a framework for measuring
fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to
valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value
measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the
fair value hierarchy are as follows:
Level
1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include debt and equity
securities (both common stock and preferred stock) that are traded in an active exchange market, as well as U.S. Treasury securities.
Level
2: Unadjusted observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets
that are not active; or other inputs that are observable or can be corroborated by observable market data for the assets or liabilities.
Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.
This category generally includes certain U.S. Government, agency mortgage-backed debt securities, non-agency structured securities, corporate
debt securities and preferred stocks.
Level
3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and
liabilities. This includes certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable
inputs.
The
following tables presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value on a recurring
basis as of:
Schedule
of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis
Description | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Balance at March 31, 2022 | |
Derivative Liabilities | |
$ | - | | |
$ | - | | |
$ | 1,175,000 | | |
$ | 1,175,000 | |
Description | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Balance at December 31, 2021 | |
Derivative Liabilities | |
$ | - | | |
$ | - | | |
$ | 221,900 | | |
$ | 221,900 | |
The
following table is a roll forward from December 31, 2021 to March 31, 2022 of the opening and closing balances for assets and liabilities
measured at fair value on a recurring basis using significant unobservable inputs (Level 3).
Schedule
Fair Value Assets and Liabilities Recurring Basis Using Significant Unobservable Inputs Level 3
| |
Derivative Liabilities | |
Opening balance December 31, 2021 | |
$ | 221,900 | |
Transfers into (out of) Level 3 | |
| | |
Total (gains) or losses for the period | |
| | |
Included in net (loss) income for the period | |
| 953,100 | |
Closing balance March 31, 2022 | |
$ | 1,175,000 | |
Change in fair value of derivative for the three
months ended March 31, 2022 was included in net loss for the period.
Fair
Value of Financial Instruments
The
Company’s financial instruments consisted of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities,
lease liabilities, and notes payable. The carrying amounts of the Company’s financial instruments other than notes payable and
lease liabilities generally approximate their fair values at March 31, 2022 and December 31, 2021 due to the short-term nature of these
instruments. The carrying amount of notes payable approximated fair value due to variable interest rates at customary terms and rates
the Company could obtain in current financing. The carrying value of lease liabilities approximate fair value due to the implicit rate
in the lease in relation to the Company’s borrowing rate and the duration of the leases.
Derivative
Liabilities
U.S.
GAAP requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and
their measurement at fair value. In assessing the convertible debt instruments, management determines if the conversion feature requires
bifurcation from the host instrument and recording of the bifurcated derivative instrument at fair value.
Once
derivative liabilities are determined, they are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease
in the fair value is recorded in results of operations as an adjustment to fair value of derivatives. The fair value of these derivative
instruments is determined using the Monte Carlo Simulation Model.
Revenue
Recognition
The
Company recognizes pharmacy revenue from dispensing prescription drugs at the time the drugs are physically delivered to a customer or
when a customer picks up their prescription or purchases merchandise at the store, which is the point in time when control transfers
to the customer. Each prescription claim is considered an arrangement with the customer and is a separate performance obligation. Payments
are received directly from the customer at the point of sale, or the customers’ insurance provider is billed electronically. For
third party medical insurance and other claims, authorization to ensure payment is obtained from the customer’s insurance provider
before the medication is dispensed to the customer. Authorization is obtained for these sales electronically and a corresponding authorization
number is issued by the customers’ insurance provider.
The
Company recognizes testing revenue when the tests are performed, and results are delivered to the customer. Each test is considered an
arrangement with the customer and is a separate performance obligation. Payment is generally received in advance from the customer.
Billings
for most prescription orders are with third-party payers, including Medicare, Medicaid, and insurance carriers. Customer returns are
nominal. Prescription revenues exceeded 86%
of total revenue for the three months ended
March 31, 2022 and 2021, respectively.
The
Company accrues an estimate of fees, including direct and indirect remuneration fees (“DIR fees”), which are assessed or
expected to be assessed by payers at some point after adjudication of a claim, as a reduction of revenue at the time revenue is recognized.
Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known.
The
following table disaggregates net revenue by categories for the three months ended March 31:
Schedule
of Disaggregates Net Revenue by Categories
| |
2022 | | |
2021 | |
Prescription revenue | |
$ | 8,605,882 | | |
$ | 8,631,048 | |
340B contract revenue | |
| 387,956 | | |
| 724,498 | |
Testing revenue | |
| 1,291,017 | | |
| 553,274 | |
Rent and other revenue | |
| 207 | | |
| 5 | |
Subtotal | |
| 10,285,062 | | |
| 9,908,825 | |
PBM fees | |
| (234,067 | ) | |
| (304,237 | ) |
Sales returns | |
| - | | |
| (124 | ) |
Revenues, net | |
$ | 10,050,995 | | |
$ | 9,604,464 | |
Cost
of Revenue
Cost
of pharmacy revenue is derived based upon vendor purchases relating to prescriptions sold, cost of testing supplies for tests administered
to patients, and point-of-sale scanning information for non-prescription sales and is adjusted based on periodic inventories. All other
costs related to revenues are expensed as incurred.
DIR
Fees
The
Company reports Direct and Indirect Remuneration (“DIR”) fees as a reduction of revenue on the accompanying Condensed
Consolidated Statements of Operations. DIR Fees are fees charged by Pharmacy Benefit Managers (“PBMs”) to pharmacies
for network participation as well as periodic reimbursement reconciliations. For some PBMs, DIR fees are charged at the time of the settlement
of a pharmacy claim. Other PBMs do not determine DIR fees at the claim settlement date, and therefore DIR fees are collected from pharmacies
after claim settlement, often as clawbacks of reimbursements based on factors that vary from plan to plan. For example, two PBMs calculate
DIR fees on a trimester basis and charge the Company for these fees as reductions of reimbursements paid to the Company 2-3 months after
the end of the trimester (e.g., DIR fees for January – April 2021 claims were charged by these PBMs in July – August 2021).
For DIR fees that are not collected at the time of claim settlement, the Company records an accrued liability at each reporting date
for estimated DIR fees that are expected to be collected by the PBMs in a future period. The estimated liability for these fees is highly
subjective and the actual amount collected may differ from the accrued liability. The uncertainty of management’s estimates is
due to inadequate disclosure to the Company by the PBMs as to exactly how these fees are calculated either at the time the DIR fees are
actually assessed and reported to the Company. The detail level of the disclosure of assessed DIR fees varies based on the information
provided by the PBM.
Vendor
Concentrations
For
the three months ended March 31, 2022 and 2021, the Company had significant vendor concentrations with one vendor. The purchases from
this significant vendor were 98% and 94% of total vendor purchases for the three months ended March 31, 2022 and 2021, respectively.
Selling,
General and Administrative Expenses
Selling
expenses primarily consist of store salaries, contract labor, occupancy costs, and expenses directly related to the stores. General and
administrative costs include advertising, insurance, professional fees, and depreciation and amortization.
Advertising
Costs
incurred for producing and communicating advertising for the Company are charged to operations as incurred. Advertising expense was $97,990
and $59,311 for the three months ended March 31, 2022 and 2021, respectively.
Share-Based
Payment Arrangements
Generally,
all forms of share-based payments, including warrants, are measured at their fair value on the awards’ grant date typically using
a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. The costs associated with
share-based compensation awards to employees and non-employee directors are measured at the grant date based on the calculated fair value
of the award and recognized as an expense ratably over the recipient’s requisite service period during which that award vests or
becomes unrestricted. Share-based compensation awards issued to non-employees for services rendered are recorded at either the fair value
of the services rendered or the fair value of the share-based payment, whichever is more readily determinable. The shares are subsequently
re-measured at their fair value at each reporting date over the service period of the awards. The expense resulting from share-based
payments is recorded in selling, general and administrative expenses in the Condensed Consolidated Statements of Operations.
Income
Taxes
Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates
expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
Progressive
Care Inc., RXMD Therapeutics and PharmCoRx 1103 are taxed as C corporations. PharmCo 901 and PharmCo 1002 are taxed as partnerships,
wherein each member is responsible for the tax liability, if any, related to its proportionate share of PharmCo 901 and PharmCo 1002’s
taxable income. Progressive Care Inc. has a 100% ownership interest in PharmCo 901 and PharmCo 1002; therefore, all of PharmCo 901 and
PharmCo 1002’s taxable income attributable to the period of ownership is included in Progressive Care Inc.’s taxable income.
The
provision for income taxes for the three months ended March 31, 2021 on the Condensed Consolidated Statements of
Operations represents the minimum state corporate tax payments. There was no current tax provision for the three months ended March
31, 2022 and 2021 because the Company did not have taxable income during those periods. Total available net operating losses
to be carried forward to future taxable years was approximately $11.6
million as of March 31, 2022, $6
million of which will expire
in various years through 2038. The temporary
differences giving rise to deferred income taxes principally relate to accelerated depreciation on property and equipment and amortization
of goodwill recorded for tax purposes, reserves for estimated doubtful accounts and inventory obsolescence and net operating losses recorded
for financial reporting purposes. The Company’s net deferred tax asset at March 31, 2022 and December 31, 2021 was fully
offset by a 100%
valuation allowance as it was not more likely than not that the tax benefits of the net deferred tax asset would be realized. The change
in the valuation allowance decreased by approximately $20,000
for the period ended March 31, 2022.
The
Company accounts for uncertainty in income taxes by recognizing a tax position in the condensed consolidated financial statements
only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions
meeting the more likely than not threshold, the amount recognized in the condensed consolidated financial statements is the largest
benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The
Company records interest and penalties related to tax uncertainties, if any, as income tax expense. Based on management’s evaluation,
the Company does not believe it has any uncertain tax positions for the three months ended March 31, 2022 and 2021.
(Loss) Income per Share
Basic
(loss) income per share (“EPS”) is computed by dividing net (loss) income available to common shareholders
by the weighted average number of common shares outstanding during the, excluding the effects of any potentially dilutive securities.
Diluted EPS gives effect to all dilutive potential of shares of common stock outstanding during the period including stock warrants,
using the treasury stock method (by using the average stock price for the period to determine the number of shares assumed to be purchased
from the exercise of stock warrants), and convertible debt, using the if converted method. Diluted EPS excludes all dilutive potential
of shares of common stock if their effect is anti-dilutive.
Paycheck
Protection Program Loan
The
Company records Paycheck Protection Program (“PPP”) loan proceeds in accordance with Accounting Standards Codification (“ASC”)
470, Debt. The Company treats the PPP loan as indebtedness, which is extinguished and recorded as a gain on debt extinguishment when
legally released by the primary obligor.
Recently
Adopted Accounting Standards
Debt
In August 2020, the FASB issued ASU 2020-06, Debt—Debt
with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic
815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which among other things, simplifies the
accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument. As a result, after adopting
the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will
account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single
unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii)
a convertible debt instrument was issued at a substantial premium. The standard became effective for the Company in the first quarter
of 2022 and did not have a material effect on the Company’s condensed consolidated financial statements.
Accounting
Pronouncements Issued but not yet Adopted
Income
Taxes
In
December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740)—simplifying the Accounting for Income Taxes, which removes
certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12
is required to be adopted for annual periods beginning after December 15, 2021, and interim periods within fiscal years beginning after
December 15, 2022. Early adoption is permitted. Management is currently evaluating the impact of the adoption of this guidance on the
Company’s condensed consolidated financial statements.
Credit
Losses
In
June 2016, the FASB issued ASU 2016-13, “Current Expected Credit Losses” (“ASU 2016-13”), which introduces an
impairment model based on expected, rather than incurred, losses. Additionally, it requires expanded disclosures regarding (a) credit
risk inherent in a portfolio and how management monitors the portfolio’s credit quality; (b) management’s estimate of expected
credit losses; and (c) changes in estimates of expected credit losses that have taken place during the period. ASU 2016-13 is effective
for fiscal years beginning after December 15, 2022. The Company has not yet quantified the impact of ASU 2016-13 on its condensed
consolidated financial statements. However, it is not expected to have a material effect on the Company’s condensed
consolidated financial statements.
Management
has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant
impact on the Company’s condensed consolidated financial statements.
Subsequent
Events
Management
has evaluated subsequent events and transactions for potential recognition or disclosure in the condensed consolidated financial
statements through May 16, 2022, the date the condensed consolidated financial statements were available to be issued.
Note
4. Liquidity and Going Concern Consideration
The
Company has sustained recurring operating losses and negative cash flows from operations over the past years. As of March 31, 2022, the
Company had an accumulated deficit of $9.9 million. For the three months ended March 31, 2022, the Company had a net
loss of $1.4 million, a loss from operations of $0.1
million, and net cash provided by
operating activities of $1.0
million. The Company’s cash and
cash equivalent position was $2.4 million as of March 31, 2022. The Company expects to continue to incur net losses for at least the next 12 months.
During
the first quarter of 2022, the Company extended
the maturity date of the Iliad Research convertible note and accrued interest of $2,298,803
to May 15, 2023. The note payable and accrued
interest can be settled by Iliad Research either through a cash payment or conversion into shares of the Company’s common stock.
Although the note holder has tendered past redemptions of the Iliad note payable in the form of common stock conversions, there are no
assurances that the note holder will convert the remaining balance of the note and accrued interest into shares of the Company’s
common stock.
Over
the past years, the Company’s growth has been funded through a combination of bank debt and lease financing. The Company
believes that it has sufficient cash balances, positive cash flows from operations, and financing commitments to meet its obligations
for the next 12 months. The attainment of profitable operations is dependent on future events, including obtaining adequate financing
to fulfill the Company’s growth and operating activities and generating a level of revenues adequate to support the Company’s
cost structure. The Company expects that it will need to raise substantial additional capital to accomplish its business plan over the
next several years. In addition, the Company may wish to selectively pursue possible acquisitions of businesses, technologies, or service
lines complementary to those of the Company in the future in order to expand its presence in the marketplace and achieve operating efficiencies.
Note
5. Accounts Receivable – Trade, net
Accounts
receivable consisted of the following at:
Schedule
of Accounts Receivable
| |
March 31, 2022 | | |
December 31, 2021 | |
Gross accounts receivable - trade | |
$ | 1,714,527 | | |
$ | 2,395,048 | |
Less: Allowance for doubtful accounts | |
| (169,400 | ) | |
| (207,200 | ) |
Accounts receivable – trade, net | |
$ | 1,545,127 | | |
$ | 2,187,848 | |
For
the three months ended March 31, 2022 and 2021, the Company recognized bad debt (recovery) expense in the amount of ($37,800) and $14,400,
respectively.
Note
6. Property and Equipment, net
Property
and equipment, net consisted of the following at:
Schedule
of Property And Equipment, Net
| |
March 31,
2022 | | |
December 31,
2021 | |
| |
| | |
| |
Building | |
$ | 1,651,069 | | |
$ | 1,651,069 | |
Building improvements | |
| 507,238 | | |
| 507,238 | |
Land | |
| 184,000 | | |
| 184,000 | |
Leasehold improvements and fixtures | |
| 276,614 | | |
| 276,614 | |
Furniture and equipment | |
| 330,291 | | |
| 330,291 | |
Computer equipment and software | |
| 101,230 | | |
| 101,230 | |
Vehicles | |
| 81,633 | | |
| 81,633 | |
Total | |
| 3,132,075 | | |
| 3,132,075 | |
Less: accumulated depreciation and amortization | |
| (742,698 | ) | |
| (708,578 | ) |
Property and equipment, net | |
$ | 2,389,377 | | |
$ | 2,423,497 | |
Depreciation
expense for the three months ended March 31, 2022 and 2021 was $42,456 and $52,271, respectively.
Note
7. Intangible Assets
Intangible
assets consisted of the following at:
Schedule
of Intangible Assets
| |
March 31, | | |
December 31, | |
| |
2022 | | |
2021 | |
Trade names | |
$ | 362,000 | | |
$ | 362,000 | |
Pharmacy records | |
| 263,000 | | |
| 263,000 | |
Non-compete agreements | |
| 166,000 | | |
| 166,000 | |
Website | |
| 67,933 | | |
| 67,933 | |
Subtotal | |
| 858,933 | | |
| 858,933 | |
Less accumulated amortization | |
| (790,751 | ) | |
| (782,566 | ) |
Net intangible assets | |
$ | 68,182 | | |
$ | 76,367 | |
Software not in service | |
| 86,424 | | |
| 76,424 | |
Total Intangible Assets, net | |
$ | 154,606 | | |
$ | 152,791 | |
Amortization
of intangible assets amounted to $8,185 and $87,008 for the three months ended March 31, 2022 and 2021, respectively. The following table
represents the total estimated amortization of intangible assets for the three succeeding years:
Schedule
of Estimated Amortization Expense for Intangible Assets
Year |
|
Amount | |
2022 (nine months) |
|
| 23,624 | |
2023 |
|
| 31,452 | |
2024 |
|
| 13,106 | |
Total |
|
$ | 68,182 | |
Note
8. Accounts Payable and Accrued Liabilities
Accounts
payable and accrued liabilities consisted of the following at:
Schedule
of Accounts Payable and Accrued Liabilities
| |
March 31, | | |
December 31, | |
| |
2022 | | |
2021 | |
Accounts payable and accrued liabilities consisted of the following: | |
| | |
| |
Accounts payable - trade | |
$ | 5,145,984 | | |
$ | 4,677,555 | |
Accrued payroll and payroll taxes | |
| 186,563 | | |
| 143,074 | |
Accrued DIR fees | |
| 774,904 | | |
| 712,002 | |
Accrued legal fees | |
| 306,588 | | |
| 306,588 | |
Other accrued liabilities | |
| 239,661 | | |
| 160,815 | |
Totals | |
$ | 6,653,700 | | |
$ | 6,000,034 | |
Note
9. Notes Payable
Notes
payable consisted of the following at:
Schedule of Notes Payable
| |
March 31, | | |
December 31, | |
| |
2022 | | |
2021 | |
A. Convertible notes payable and accrued interest - collateralized | |
$ | 2,298,803 | | |
$ | 2,143,891 | |
B. Mortgage note payable – commercial bank - collateralized | |
| 1,287,311 | | |
| 1,307,562 | |
C. Note payable – uncollateralized | |
| 25,000 | | |
| 25,000 | |
D. Note payable - collateralized | |
| 45,989 | | |
| 52,231 | |
Insurance premium financing | |
| 30,430 | | |
| 68,164 | |
Subtotal | |
| 3,687,533 | | |
| 3,596,848 | |
Less Unamortized debt discount | |
| - | | |
| (198,677 | ) |
Less Unamortized debt issuance costs | |
| - | | |
| (575 | ) |
Less Unamortized investment length premium | |
| - | | |
| (86,618 | ) |
Total | |
| 3,687,533 | | |
| 3,310,978 | |
Less: Current portion of notes payable | |
| (163,937 | ) | |
| (202,184 | ) |
Long-term portion of notes payable | |
$ | 3,523,596 | | |
$ | 3,108,794 | |
The
corresponding notes payable above are more fully discussed below:
(A)
Convertible Notes Payable – collateralized
Iliad
Research and Trading, L.P.
On
March 6, 2019, Progressive entered a Securities Purchase Agreement (the “Purchase Agreement”) with Iliad Research and Trading,
L.P. (“Iliad Research”), a Utah limited partnership, in the amount of $3,310,000,
which included a $300,000
Original Issue Discount (“OID”) and
$10,000
in debt issuance costs for the transaction (“the
Iliad Research note”). The Iliad Research note is comprised of two tranches consisting of an initial tranche in the
amount of $2,425,000
and a second tranche in the amount of $885,000.
The initial tranche consisted of the initial cash purchase price of $2,425,000,
$115,000
of the OID and the debt issuance costs of $10,000.
The remaining OID of $185,000
was
allocated to the second tranche. The Iliad Research note is convertible into shares of common stock ($0.0001
par value per share) in 1 year at the average
of the two lowest closing trading prices during the twenty trading days immediately preceding the applicable conversion. The original
Iliad Research note maturity date was April
15, 2022. In March 2022, the Company elected
to extend the Iliad Research note to May
15, 2022 (“the Maturity Date”)
and obtained the right to further extend the maturity date of the Iliad Research note to May 15, 2023. The Iliad Research note accrues
interest at the rate of 10%
per annum and the entire unpaid principal balance plus all accrued and unpaid interest are due on the Maturity Date.
An
investment length premium in the amount of $168,619 was applied to the outstanding balance of the Iliad Research note in September 2020,
another investment length premium in the amount of $136,486 was applied to the outstanding balance in March 2021, and another investment
length premium in the amount of $117,619 was applied to the outstanding balance in September 2021. The investment length premiums were
calculated at a 5% premium on the outstanding note balance when the note was still outstanding at (a) eighteen months from the effective
date, (b) twenty-four months from the effective date, and (c) thirty months from the effective date.
The
Iliad Research note includes a provision that limits the volume of sales of common stock shares received by Iliad Research from
note conversions (“Conversion Shares”). Iliad Research agreed that, with respect to the sale of Conversion Shares, in any
given calendar week its net sales of Conversion Shares shall not exceed the greater of (i)
ten percent (10%) of Progressive’s Common Stock dollar trading volume (the “Trading Volume”) in such week (which, for
purposes hereof, means the number of shares traded during such calendar week multiplied by the volume weighted average price per share
for such week), and (ii) $100,000.00 (the “Volume Limitation”); provided; however, that if Lender’s Net Sales are less
than the Volume Limitation for any given week, then in the following week (or two (2) weeks in the case of any week where the Closing
Trade Price on any given day during that week is 25% greater than the previous week’s VWAP) Lender shall be allowed to sell an
additional amount of Conversion Shares equal to the difference between the amount Lender was allowed to sell and the amount Lender actually
sold.
In
the event Iliad Research breaches the Volume Limitation where its Net Sales of Conversion Shares during any calendar week exceed the
dollar volume it is permitted to sell during such week pursuant to the Volume Limitation (such excess, the “Excess Sales”),
then in such event Progressive shall be entitled to reduce the Outstanding Balance of the Iliad Research note by an amount equal to such
Excess Sales upon delivery of written notice to Iliad Research setting forth its basis for such reduction (the “Outstanding Balance
Reduction”).
The
volume of Conversion Shares sales exceeded the Volume Limitation in June 2021, which resulted in Excess Sales of $180,000
and a corresponding Outstanding Balance Reduction
in the Iliad Research note carrying value of $180,000
as of December 31, 2021. The Company reported
the Outstanding Balance Reduction as a Gain on Debt Extinguishment in the amount of $180,000
on the Company’s Consolidated Statements
of Operations for the year ended December 31, 2021.
Progressive
Care filed a demand (“the Company Demand”) with Iliad Research on December 14, 2021, that alleged breaches of the
volume limitation provisions of the Iliad Research note, as well as a previous note agreement with an affiliate of Iliad Research,
Chicago Venture Partners, LP (“CVP”), (“the CVP note”). The CVP Note had previously been paid off in 2020.
On January 7, 2022, in response to the Company Demand, Iliad Research and CVP filed a complaint with the Third Judicial District
Court of Salt Lake County, State of Utah, as well as an Arbitration Notice pursuant to the CVP and Iliad Research Purchase
Agreements.
On
January 20, 2022, Progressive Care entered into an agreement with Iliad Research and CVP (“the Settlement Agreement”)
wherein the investors agreed to resolve various demands and complaints related to the note agreements with the two investors.
In
the Settlement Agreement, the parties agreed to the following:
| 1. | The
Maturity Date of the Iliad Research Note was extended to April 15, 2022. Progressive
Care also was granted the right to extend the Maturity Date for an additional month
to May 15, 2022 at its election by providing written notice of such election to Iliad Research.
In the event Progressive Care elects to extend the Maturity Date to May 15, 2022,
then the outstanding balance of the Iliad Research Note will increase by two percent
(2%). |
| 2. | Iliad
Research and any entity affiliated with Iliad Research agreed not to sell any shares of Progressive
Care common stock for the period (“the Standstill Period”) beginning on January
20, 2022 (“the Effective Date” of the Settlement Agreement) and ending on the
Maturity Date of the Iliad Research Note, as amended by the Settlement Agreement.
In addition, Iliad Research agreed not to submit any Redemption Notices under the Iliad Research
Note during the Standstill Period, so long as no event of default occurs under the Iliad
Research Note. |
| 3. | CVP
agreed to pay $175,000
via
wire transfer within two (2) business days of the Effective Date as settlement of the alleged
breaches of the volume limitation provisions of the CVP Note. Upon receipt of the
payment, the Securities Purchase agreement between Progressive Care and CVP and all other
documents entered into in connection therewith, were deemed to be terminated and of not further
force or effect. |
| 4. | Iliad
Research agreed to a decrease in the balance of the Iliad Research Note, effective
as of May 31, 2021 of $180,000
as
settlement of the alleged breaches of the volume limitation provisions of the Iliad Research
Note. In the event the Iliad Research Note is not repaid by February 16, 2022,
the outstanding balance of the Iliad Research Note will increase in the amount of
$100,000. |
| 5. | If
Progressive Care exercises its right to prepay the Iliad Research Note, then it will
make a payment to Iliad Research in an amount in cash equal to 105%
of the portion of the Outstanding Balance that it elected to repay (“the Prepayment
Amount”). Progressive Care also has the right to treat up to ten percent (10%)
of the Prepayment Amount as a Conversion and satisfy such portion of the Prepayment Amount
by delivering common stock shares to Iliad Research. |
As
a result of item 3 above in the Settlement Agreement, the $175,000
received
as settlement for alleged breaches on the volume limitations provision on the CVP Note was recorded as a Gain on Debt Settlement
during the three months ended March 31, 2022.
As
a result of item 4 above in the Settlement Agreement, the Outstanding Balance Reduction in the Iliad Research note carrying value of
$149,346
was recorded as a Gain on Debt Extinguishment
during the three months ended March 31, 2021. The Iliad Research Note was not repaid by February 16, 2022 and the principal balance
increased by $100,000
to $1,410,744
as of March 31, 2022. The $100,000
increase in the Iliad Research note balance
was recorded as Interest Expense during the three months ended March 31, 2022.
On May 13, 2022, Iliad
Research agreed to (a) extend the maturity date of the Iliad Research Note to May
15, 2023 (the
“Extension”), and (b) not seek to redeem any portion of the outstanding Iliad Research Note or sell any shares of the Company’s
common stock through June 15, 2022 (the “Standstill Period 1”). The Company has the option to extend the Standstill Period
through July 15, 2022 (“Standstill Period 2”). In consideration for the above, the outstanding balance of the
Iliad Research note will be increased by: (a) an Extension Fee of $237,173,
(b) a Standstill Fee of $47,435
for Standstill Period 1, and (c) a Standstill Fee of $53,607
for Standstill Period 2, if elected. As a result, the outstanding balance of the Iliad Research note, inclusive of Extension and Standstill
Period 1 fees, is $2,656,336
at May 13, 2022.
The
note balance has been partially satisfied through a series of redemption notices for conversion of note principal and accrued interest
into shares of Progressive common stock at various conversion rates.
The
principal balance outstanding on the Iliad Research note was $1,410,744
and $1,310,744
at March 31, 2022 and December 31, 2021, respectively.
Accrued interest on the Iliad Research note at March 31, 2022 and December 31, 2021, was $888,059
and $833,147,
respectively, and such amounts are included in long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.
The
Company has identified conversion features embedded within the Iliad Research note. The Company has determined that the conversion features
represent an embedded derivative. Accordingly, the embedded conversion feature was bifurcated from the debt host and accounted for as
a derivative liability. On March 6, 2019, the Company recorded a derivative liability on the first tranche in the amount of $1,351,000.
On June 4, 2019, the Company recorded a derivative liability on the second tranche in the amount of $614,000.
For the three months ended March 31, 2022 and 2021, the Company recorded a Change in Fair Value of the Derivative Liability in the amount
of ($953,100) and $426,680,
respectively. The derivative liability balance on the Iliad Research note at March 31, 2022 and December 31, 2021 was $1,175,000
and $221,900,
respectively.
At
inception, the fair value of the derivative instrument has been recorded as a liability on the Condensed Consolidated Balance Sheets
with the corresponding amount recorded as a discount to the note. The discount was accreted from the issuance date to December 31,
2021, with a corresponding charge to interest expense. The change in the fair value of the derivative liability was recorded in other
income or expenses in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and
2021, with the offset to the derivative liability on the Condensed Consolidated Balance Sheets. The fair value of the embedded
derivative liability was determined using the Monte Carlo Simulation model on the issuance date.
Debt
Issuance Costs, Debt Discount and Investment Length Premium:
Debt
Issuance Costs consist of fees incurred through securing financing from Iliad Research on March 6, 2019. Debt Discount consists of the
discount recorded upon recognition of the derivative liability upon issuance of the first and second tranches. Investment length premium
is calculated at a 5% premium on the outstanding balance when the note is still outstanding at (a) eighteen months from the effective
date, (b) twenty-four months from the effective date, and (c) thirty months from the effective date.
Debt
issuance costs, debt discount and investment length premium are amortized to interest expense over the term of the related debt using
the effective interest method. Total amortization expense for the three months ended March 31, 2022 and 2021 was $285,870
and $224,130,
respectively.
(B)
Mortgage Note Payable – collateralized
In
2018, PharmCo 901 closed on the purchase of land and building located at 400 Ansin Boulevard, Hallandale Beach, Florida. The purchase
price was financed in part through a mortgage note and security agreement entered into with a commercial lender in the amount of $1,530,000.
The promissory note is collateralized by the land and building, bears interest at a fixed rate of 4.75% per annum, matures on December
14, 2028 and is subject to a prepayment penalty. Principal and interest will be repaid through 119 regular payments of $11,901 that began
in January 2019, with the final payment of all principal and accrued interest not yet paid on December 14, 2028. Note repayment is guaranteed
by Progressive Care Inc. The balance outstanding on the mortgage payable was $1,287,311 and $1,307,562 at March 31, 2022 and December
31, 2021, respectively.
(C)
Note Payable – Uncollateralized
As
of March 31, 2022 and December 31, 2021, the uncollateralized note payable represents a non-interest-bearing loan that is due on demand
from an investor.
(D)
Note Payable – Collateralized
In
September 2019, the Company entered into a note obligation with a commercial lender, the proceeds from which were used to pay off a capital
lease obligation on pharmacy equipment in the amount of $85,429. The terms of the promissory note payable require 48 monthly payments
of $2,015, including interest at 6.5%. The balance outstanding on the note payable was $34,453 and $39,913 at March 31, 2022 and December
31, 2021, respectively. The promissory note is secured by equipment with a net book value of $30,857 and $35,729 at March 31, 2022 and
December 31, 2021, respectively.
In
April 2021, the Company entered into a note obligation with a commercial lender, the proceeds from which were used to purchase pharmacy
equipment in the amount of $29,657. During September 2021, pharmacy equipment was returned since the installation was cancelled and the
note was amended. The amended promissory note payable requires 46 monthly payments of $331, including interest at 6.9%. The balance outstanding
at March 31, 2022 and December 31, 2021 on the note payable was $11,534 and $12,319, respectively. The remaining equipment was written
off during September 2021.
(E)
U.S. CARES Act PPP Loans – Uncollateralized
The
Paycheck Protection Program (“PPP”), established as part of the Coronavirus Aid, Relief and Economic Security Act (“U.S.
CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of
the qualifying business. The loans and accrued interest are forgivable after eight-weeks or twenty-four-weeks as long as the borrower
used the loan proceeds for eligible purposes, including payroll, mortgage interest payments, employee benefits, rent and utilities, and
maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries
during the eight-week or twenty-four week periods. The unforgiven portion of the PPP loans are payable over two or five years at an interest
rate of 1%, with a deferral of payments for the first nine months. Thereafter, any unforgiven principal and interest are payable in 18
equal monthly installments.
The
Company applied for forgiveness of the PPP loan received by PharmCo 1103 in April 2020 in the amount of $421,400
and on January 7, 2021, received notification
from the lender that the U.S. Small Business Administration approved the forgiveness of the U.S. CARES Act PPP Loan for PharmCo 1103.
The debt forgiveness in the amount of $421,400
is recorded as a Gain on Debt Extinguishment
in the Company’s Condensed Consolidated Statements of Operations for the three months ended March 31, 2021.
Future
principal maturities of notes payable are as follows:
Schedule
of Future Principle Maturities
Year | |
Amount | |
2022
(nine months) | |
$ | 137,956 | |
2023 | |
| 2,403,640 | |
2024 | |
| 93,408 | |
2025 | |
| 96,228 | |
Thereafter | |
| 956,301 | |
Total | |
$ | 3,687,533 | |
Interest
expense on these notes payable exclusive of debt discount and debt issue cost amortization, was $172,642
and $95,669
for the three months ended March 31, 2022 and
2021, respectively.
Note
10. Lease Obligations
The
Company has entered into a number of lease arrangements under which we are the lessee. Three of our leases are classified as finance
leases and three of our leases are classified as operating leases. In addition, we have elected the short-term lease practical expedient
in ASC Topic 842 related to real estate leases with terms of one year or less and short-term leases of equipment used in our pharmacy
locations. The following is a summary of our lease arrangements.
Finance
Leases
In
May 2018, the Company entered into a finance lease obligation to purchase pharmacy equipment with a cost of $114,897. The
terms of the lease agreement require monthly payments of $1,678
plus applicable tax over 84 months ending March 2025 including interest at the rate of 6%. The
finance lease obligation is secured by equipment with a net book value of $50,601
and $54,706
at
March 31, 2022 and December 31, 2021, respectively.
The
Company assumed an equipment finance lease obligation for medication dispensing equipment from the acquisition of PharmCo 1002 in July
2018. The lease expired in March 2022. The finance lease obligation was secured by equipment with a net book value of $0
at
March 31, 2022 and December 31, 2021, respectively.
In
December 2020, the Company entered into an interest-free finance lease obligation to purchase computer servers with a cost of $50,793. The
terms of the lease agreement require monthly payments of $1,411
plus applicable tax over 36 months ending November 2023. The
finance lease obligation is secured by equipment with a net book value of $28,218
and $32,451
at
March 31, 2022 and December 31, 2021, respectively.
Operating
Leases
The
Company entered into a lease agreement for its Orlando pharmacy on August 1, 2020 (the lease commencement date). The term of the lease
is 66 months with a termination date of February 1, 2026. The lease agreement calls for monthly payments that began on February 1, 2021,
of $4,310, with an escalating payment schedule each year thereafter.
The
Company leases its North Miami Beach pharmacy locations under an operating lease agreement with a lease commencement date on September
1, 2021. The term of the lease is 60 months with a termination date of August 31, 2026. The lease calls for monthly payments of $5,237,
with an escalating payment schedule each year thereafter.
The
Company also leases its Palm Beach County pharmacy locations under operating lease agreements expiring in March 2024.
The
Company recognized lease costs associated with all leases as follows:
Schedule
of Lease Costs Associated with All Leases
| |
2022 | | |
2021 | |
| |
For
the Three Months Ended March
31, | |
| |
2022 | | |
2021 | |
Operating
lease cost: | |
| | | |
| | |
Fixed
rent expense | |
$ | 47,377 | | |
$ | 207,272 | |
Finance
lease cost: | |
| | | |
| | |
Amortization
of right of use assets (included in depreciation expense) | |
| 8,336 | | |
| 8,336 | |
Interest
expense | |
| 869 | | |
| 1,990 | |
Total
Lease Costs | |
$ | 56,582 | | |
$ | 217,598 | |
Supplemental
cash flow information related to leases was as follows:
Schedule
of Supplemental Cash Flow Information Related to Leases
| |
2022 | | |
2021 | |
| |
For
the Three Months Ended March
31, | |
| |
2022 | | |
2021 | |
Cash
paid for amounts included in the measurement of lease
liabilities: | |
| | | |
| | |
Operating
cash flows from operating leases | |
$ | 30,260 | | |
$ | 49,853 | |
Financing
cash flows from finance leases | |
| 9,619 | | |
| 15,286 | |
Total
cash paid for lease liabilities | |
$ | 39,879 | | |
$ | 65,139 | |
Supplemental
balance sheet information related to leases was as follows:
Schedule
of Supplemental Balance Sheet Information Related to Leases
| |
March
31, 2022 | | |
December
31, 2021 | |
Operating
leases: | |
| | | |
| | |
Operating
lease right-of-use assets, net | |
$ | 559,051 | | |
$ | 595,790 | |
| |
| | | |
| | |
Operating
lease liabilities: | |
| | | |
| | |
Current
portion | |
| 153,404 | | |
| 149,744 | |
Long-term
portion | |
| 438,989 | | |
| 469,665 | |
| |
| | | |
| | |
Finance
leases: | |
| | | |
| | |
Finance
lease right-of-use assets, net | |
| 78,821 | | |
| 87,156 | |
| |
| | | |
| | |
Finance
lease liabilities: | |
| | | |
| | |
Current
portion | |
| 34,230 | | |
| 33,976 | |
Long-term
portion | |
| 49,159 | | |
| 57,814 | |
Maturities
of lease liabilities were as follows:
Schedule
of Maturities of lease liabilities
Year | |
Finance
Lease | | |
Operating
Lease | | |
Total
Future Lease Commitments | |
2022
(nine months) | |
$ | 27,805 | | |
$ | 132,284 | | |
$ | 160,089 | |
2023 | |
| 35,662 | | |
| 181,787 | | |
| 217,449 | |
2024 | |
| 20,142 | | |
| 144,583 | | |
| 164,725 | |
2025 | |
| 5,035 | | |
| 134,933 | | |
| 139,968 | |
2026 | |
| - | | |
| 53,459 | | |
| 53,459 | |
Total
lease payments to be paid | |
| 88,644 | | |
| 647,046 | | |
| 735,690 | |
Less:
Future interest expense | |
| (5,255 | ) | |
| (54,653 | ) | |
| (59,908 | ) |
Lease
liabilities | |
| 83,389 | | |
| 592,393 | | |
| 675,782 | |
Less:
current maturities | |
| (34,230 | ) | |
| (153,404 | ) | |
| (187,634 | ) |
Long-term
portion of lease liabilities | |
$ | 49,159 | | |
$ | 438,989 | | |
$ | 488,148 | |
Note
11. Stockholders’ (Deficit) Equity
Preferred
Stock
The
Series A preferred stock is a non-dividend producing instrument that ranks superior to the Company’s common stock. Each one (1)
share of the Series A Preferred Stock shall have voting rights equal to (x) 0.019607 multiplied by the total issued and outstanding
common stock and Preferred Stock eligible to vote at the time of the respective vote (the “Numerator”), divided
by (y) 0.49, minus (z) the Numerator.
With
respect to all matters upon which stockholders are entitled to vote or to which shareholders are entitled to give consent, the holders
of the outstanding shares of Series A Preferred Stock shall vote together with the holders of common stock without regard to class, except
as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws.
On
July 11, 2014, the board of directors approved the issuance of 51 shares of the Company’s Series A Preferred Stock to a certain
employee of the Company, which is equal to 50.99% of the total voting power of all issued and outstanding voting capital of the Company
in satisfaction of $20,000 in past due debt. On October 15, 2020, the preferred shares were transferred to a trust whose beneficiary
is related to the employee. These issued shares of preferred stock are outstanding as of March 31, 2022 and December 31, 2021.
Note
12. Commitments and Contingencies
Legal
Matters
On May 3, 2022, a complaint was filed by the Plaintiff
Positive Health Alliance, Inc. (“PHA”) against PharmCo LLC, a wholly owned subsidiary of the Company, in the U.S. Circuit
Court of Miami Dade, Florida, alleging that defendant failed to pay amounts due and owing to PHA under the parties’ contract for
discounted prescription drugs. PHA is seeking judgment against PharmCo for compensatory damages in the amount of $407,502.97, plus attorneys’
fees and costs. Settlement negotiations with PHA are ongoing. The $407,502.97 was recorded in Accounts Payable and Accrued Liabilities
in the Company’s Condensed Consolidated Balance Sheets at March 31, 2022 and December 31, 2021.
Note
13. Related Party Transactions
During
the years ended December 31, 2021, and 2020, the Company had a consulting arrangement with Spark Financial Consulting (“Spark”),
which is a consulting company owned by an employee and beneficial shareholder of the Company. Spark provides business development services
including but not limited to recruiting, targeting and evaluation of potential mergers and acquisitions, finding third party contractors
and assisting with related negotiations in exchange for a monthly fee of $16,000
in 2021. Additionally, Spark may be entitled
to additional fees for additional consulting services. During the three months ended March 31 and 2021, the Company paid Spark $48,000. The agreement was terminated during the third quarter of 2021.
The
Company has an employment agreement (the “Agreement”) with a certain pharmacist, Head of the Compounding Department, who
is the first paternal cousin to the beneficial shareholder and employee of the Company. In consideration for duties performed including
but not limited to marketing, patient consultation, formulary development, patient and physician education, training, recruitment, sales
management, as well as pharmacist responsibilities, the Company agreed to provide monthly compensation of $15,000
or $10,000
per month plus 5%
commission on monthly gross profits generated by the Compounding Department, whichever is greater. During the three months ended March
31 2021, payments to the pharmacist was $30,245.
The agreement was terminated during the third quarter of 2021.
Note
14. Retirement Plan
The
Company sponsors a 401(k) retirement plan (“the Plan”) covering qualified employees of PharmCo 901, PharmCo 1002 and FPRX,
as defined. Employees who have been employed more than one year are eligible to participate in the Plan. Through March 31, 2021, the
Company matched the employee’s contribution up to a maximum of 3% of the eligible employee’s compensation. The Company contributed
approximately $0 and $2,200 in matching contributions for the three months ended March 31, 2022 and 2021, respectively.